The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Management of Male Breast Cancer: ASCO Guideline
Abstract
PURPOSE: To develop recommendations concerning the management of male breast cancer. METHODS: ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process. RESULTS: Twenty-six descriptive reports or observational studies met eligibility criteria and formed the evidentiary basis for the recommendations. RECOMMENDATIONS: Many of the management approaches used for men with breast cancer are like those used for women. Men with hormone receptor–positive breast cancer who are candidates for adjuvant endocrine therapy should be offered tamoxifen for an initial duration of five years; those with a contraindication to tamoxifen may be offered a gonadotropin-releasing hormone agonist/antagonist plus aromatase inhibitor. Men who have completed five years of tamoxifen, have tolerated therapy, and still have a high risk of recurrence may be offered an additional five years of therapy. Men with early-stage disease should not be treated with bone-modifying agents to prevent recurrence, but could still receive these agents to prevent or treat osteoporosis. Men with advanced or metastatic disease should be offered endocrine therapy as first-line therapy, except in cases of visceral crisis or rapidly progressive disease. Targeted systemic therapy may be used to treat advanced or metastatic cancer using the same indications and combinations offered to women. Ipsilateral annual mammogram should be offered to men with a history of breast cancer treated with lumpectomy regardless of genetic predisposition; contralateral annual mammogram may be offered to men with a history of breast cancer and a genetic predisposing mutation. Breast magnetic resonance imaging is not recommended routinely. Genetic counseling and germline genetic testing of cancer predisposition genes should be offered to all men with breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Antoniou, A., Pharoah, P. D. P., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, Å., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/375033 · Cited by 3,680
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
The CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene
The Breast Cancer Susceptibility Collaboration (UK), Rahman, N., Seal, S., Thompson, D., Kelly, P., Renwick, A., Elliott, A., Reid, S., Spanova, K., Barfoot, R., et al. (2007) · Nature Genetics · doi:10.1038/ng1959 · Cited by 1,003
Burstein, H. J., Lacchetti, C., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. A., Giordano, S. H., Hudis, C. A., Solky, A. J., Stearns, V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01160 · Cited by 636
Self-citationRugo, H. S., Rumble, R. B., Macrae, E., Barton, D. L., Connolly, H. K., Dickler, M. N., Fallowfield, L., Fowble, B., Ingle, J. N., Jahanzeb, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1487 · Cited by 633
Khatcheressian, J. L., Hurley, P., Bantug, E., Esserman, L. J., Grunfeld, E., Halberg, F., Hantel, A., Henry, N. L., Muss, H. B., Smith, T. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9859 · Cited by 626
Self-citationPatient-clinician communication: American Society of Clinical Oncology consensus guideline
Gilligan, T., Coyle, N., Frankel, R. M., Berry, D. L., Bohlke, K., Epstein, R. M., Finlay, E., Jackson, V. A., Lathan, C. S., Loprinzi, C. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.2311 · Cited by 610
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
Korde, L. A., Zujewski, J. A., Kamin, L., Giordano, S., Domchek, S., Anderson, W. F., Bartlett, J. M. S., Gelmon, K., Nahleh, Z., Bergh, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5729 · Cited by 487
Self-citationBreast Cancer Risk Among Male BRCA1 and BRCA2 Mutation Carriers
Tai, Y. C., Domchek, S., Parmigiani, G., & Chen, S. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm203 · Cited by 430
NCCN Task Force Report: Bone Health in Cancer Care
Gralow, J. R., Biermann, J. S., Farooki, A., Fornier, M. N., Gagel, R. F., Kumar, R., Litsas, G., McKay, R., Podoloff, D. A., Srinivas, S., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0215 · Cited by 412
Self-citationCardoso, F., Bartlett, J. M. S., Slaets, L., van Deurzen, C. H. M., van Leeuwen-Stok, E., Porter, P., Linderholm, B., Hedenfalk, I., Schröder, C., Martens, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx651 · Cited by 405
Self-citationMale breast cancer: a disease distinct from female breast cancer
Gucalp, A., Traina, T. A., Eisner, J. R., Parker, J. S., Selitsky, S. R., Park, B. H., Elias, A. D., Baskin-Bey, E. S., & Cardoso, F. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4921-9 · Cited by 392
Self-citationGiordano, S. H. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1707939 · Cited by 390
Self-citationde Blok, C. J. M., Wiepjes, C. M., Nota, N. M., van Engelen, K., Adank, M. A., Dreijerink, K. M. A., Barbé, E., Konings, I. R. H. M., & den Heijer, M. (2019) · BMJ · doi:10.1136/bmj.l1652 · Cited by 366
Goss, P. E., Reid, C., Pintilie, M., Lim, R., & Miller, N. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990201)85:3<629::aid-cncr13>3.0.co;2-v · Cited by 325
Burstein, H. J., Lacchetti, C., & Griggs, J. J. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00617 · Cited by 248
Carcinoma of the breast in males
Donegan, W. L., Redlich, P. N., Lang, P., & Gall, M. T. (1998) · Cancer · Cited by 206
Adjuvant systemic therapy for male breast carcinoma
Giordano, S. H., Perkins, G. H., Broglio, K., Garcia, S. G., Middleton, L. P., Buzdar, A. U., & Hortobagyi, G. N. (2005) · Cancer · doi:10.1002/cncr.21526 · Cited by 200
Self-citationBRCA1 and BRCA2 mutations in a population-based study of male breast cancer
Basham, V. M., Lipscombe, J. M., Ward, J. M., Gayther, S. A., Ponder, B. A., Easton, D. F., & Pharoah, P. D. (2001) · Breast Cancer Research · doi:10.1186/bcr419 · Cited by 191
Male breast cancer in Cowden syndrome patients with germline PTEN mutations
Fackenthal, J. D., Marsh, D. J., Richardson, A.-L., Cummings, S. A., Eng, C., Robinson, B. G., & Olopade, O. I. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.3.159 · Cited by 190
Loblaw, D. A., Prestrud, A. A., Somerfield, M. R., Oliver, T. K., Brouwers, M. C., Nam, R. K., Lyman, G. H., & Basch, E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0489 · Cited by 189
Self-citationMoredo Anelli, T. F., Anelli, A., Tran, K. N., Lebwohl, D. E., & Borgen, P. I. (1994) · Cancer · doi:10.1002/1097-0142(19940701)74:1<74::aid-cncr2820740113>3.0.co;2-# · Cited by 180
Giordano, S. H., Temin, S., Chandarlapaty, S., Crews, J. R., Esteva, F. J., Kirshner, J. J., Krop, I. E., Levinson, J., Lin, N. U., Modi, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2697 · Cited by 176
Self-citationAdjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
Eggemann, H., Ignatov, A., Smith, B. J., Altmann, U., von Minckwitz, G., Röhl, F. W., Jahn, M., & Costa, S.-D. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2355-3 · Cited by 164
Irani, J., Salomon, L., Oba, R., Bouchard, P., & Mottet, N. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70338-9 · Cited by 153
Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results
Pritzlaff, M., Summerour, P., McFarland, R. E., Li, S., Reineke, P., Dolinsky, J. S., Goldgar, D. E., Shimelis, H., Couch, F. J., Chao, E., et al. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4085-4 · Cited by 153
Resnick, M. J., Lacchetti, C., Bergman, J., Hauke, R. J., Hoffman, K. E., Kungel, T. M., Morgans, A. K., & Penson, D. F. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2557 · Cited by 138
Retrospective review of male breast cancer patients: analysis of tamoxifen-related side-effects
Pemmaraju, N., Munsell, M. F., Hortobágyi, G. N., & Giordano, S. H. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr459 · Cited by 133
Self-citationPsychological Distress in Men With Breast Cancer
Brain, K., Williams, B., Iredale, R., France, L., & Gray, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.064 · Cited by 89
Aromatase inhibition in male breast cancer patients: biological and clinical implications
Doyen, J., Italiano, A., Largillier, R., Ferrero, J.-M., Fontana, X., & Thyss, A. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp450 · Cited by 87
Henry, N. L., Somerfield, M. R., Abramson, V. G., Ismaila, N., Allison, K. H., Anders, C. K., Chingos, D. T., Eisen, A. F., Ferrari, B. L., Openshaw, T. H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00948 · Cited by 86
Self-citationMale cancer: a qualitative study of male breast cancer
France, L., Michie, S., Barrett-Lee, P. J., Brain, K. E., Harper, P. S., & Gray, J. (2000) · The Breast · doi:10.1054/brst.2000.0173 · Cited by 85
The experiences of men with breast cancer in the United Kingdom
Iredale, R., Brain, K. E., Williams, B., France, E., & Gray, J. R. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.09.027 · Cited by 80
Breast cancer in men in the United States
Harlan, L. C., Zujewski, J. A., Goodman, M. T., & Stevens, J. L. (2010) · Cancer · doi:10.1002/cncr.25153 · Cited by 79
Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer
Xu, S., Yang, Y., Tao, W., Song, Y., Chen, Y., Ren, Y., Liu, J., & Pang, D. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2286-z · Cited by 69
Men With a “Woman’s Disease”: Stigmatization of Male Breast Cancer Patients—A Mixed Methods Analysis
Midding, E., Halbach, S. M., Kowalski, C., Weber, R. K., Würstlein, R., & Ernstmann, N. (2018) · American Journal of Men s Health · doi:10.1177/1557988318799025 · Cited by 66
Outcome of non-metastatic male breast cancer: 118 patients
Arslan, Ü. Y., Öksüzoğlu, B. Ç., Özdemir, N., Aksoy, S., Alkış, N., Gök, A., Ma, K., Gümüş, M., Berk, V., Uncu, D., et al. (2011) · Medical Oncology · doi:10.1007/s12032-011-9978-9 · Cited by 61
‘Marginalised malignancies’: A qualitative synthesis of men's accounts of living with breast cancer
Quincey, K., Williamson, I. R., & Winstanley, S. (2015) · Social Science & Medicine · doi:10.1016/j.socscimed.2015.11.032 · Cited by 60
Donovan, T., & Flynn, M. (2007) · Cancer Nursing · doi:10.1097/01.ncc.0000300173.18584.37 · Cited by 57
Zagouri, F., Sergentanis, T. Ν., Koutoulidis, V., Sparber, C., Steger, G. G., Dubsky, P. C., Zografos, G. C., Ψαλτοπούλου, Θ., Gnant, M., Dimopoulos, M. A., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.255 · Cited by 55
Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer
Eggemann, H., Altmann, U., Costa, S., et al. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2539-7 · Cited by 50
Fulvestrant and male breast cancer: a pooled analysis
Zagouri, F., Sergentanis, T. Ν., Chrysikos, D., Dimopoulos, M. A., & Ψαλτοπούλου, Θ. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3240-z · Cited by 43
Lauro, L. D., Pizzuti, L., Barba, M., Sergi, D., Sperduti, I., Mottolese, M., Amoreo, C. A., Belli, F., Vici, P., Speirs, V., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0147-z · Cited by 40
Quality of life and symptoms in male breast cancer survivors
Ruddy, K. J., Giobbie‐Hurder, A., Giordano, S. H., Goldfarb, S. B., Kereakoglow, S., Winer, E. P., & Partridge, A. H. (2013) · The Breast · doi:10.1016/j.breast.2012.12.014 · Cited by 39
Self-citationLetrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer
Lauro, L. D., Vici, P., Medico, P. D., Laudadio, L., Tomao, S., Giannarelli, D., Pizzuti, L., Sergi, D., Barba, M., & Maugeri‐Saccà, M. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2675-y · Cited by 35
Zhao, W., Li, S., Dabei, T., Ying, P., Zhipeng, W., Lei, Z., He, X., Jingshu, G., Hongtao, S., & Qingyuan, Z. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0278 · Cited by 28
Lauro, L. D., Vici, P., Barba, M., Pizzuti, L., Sergi, D., Rinaldi, M., Benedetto, A. D., Sperduti, I., Shaaban, A. M., Speirs, V., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3138-9 · Cited by 25
Cited by
Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Burstein, H. J., Somerfield, M. R., Barton, D. L., Dorris, A., Fallowfield, L. J., Jain, D., Johnston, S. R. D., Korde, L. A., Litton, J. K., Macrae, E. R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01392 · Cited by 317
Self-citation
Metadata
- Authors
- Hassett, M. J., Somerfield, M. R., Baker, E. R., Cardoso, F., Kansal, K. J., Kwait, D. C., Plichta, J. K., Ricker, C., Roshal, A., Ruddy, K. J., Safer, J. D., Van Poznak, C., Yung, R. L., & Giordano, S. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-06-01
- Volume
- 38
- Issue
- 16
- Pages
- 1849-1863
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3006424097
- Cited by
- 263
- References
- 55
- FWCI
- 23.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.